Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration
- PMID: 24116849
- PMCID: PMC3976615
- DOI: 10.1111/bph.12453
Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration
Abstract
The eukaryotic cell possesses specialized pathways to turn over and degrade redundant proteins and organelles. Each pathway is unique and responsible for degradation of distinctive cytosolic material. The ubiquitin-proteasome system and autophagy (chaperone-mediated, macro, micro and organelle specific) act synergistically to maintain proteostasis. Defects in this equilibrium can be deleterious at cellular and organism level, giving rise to various disease states. Dysfunction of quality control pathways are implicated in neurodegenerative diseases and appear particularly important in Parkinson's disease and the lysosomal storage disorders. Neurodegeneration resulting from impaired degradation of ubiquitinated proteins and α-synuclein is often accompanied by mitochondrial dysfunction. Mitochondria have evolved to control a diverse number of processes, including cellular energy production, calcium signalling and apoptosis, and like every other organelle within the cell, they must be 'recycled.' Failure to do so is potentially lethal as these once indispensible organelles become destructive, leaking reactive oxygen species and activating the intrinsic cell death pathway. This process is paramount in neurons which have an absolute dependence on mitochondrial oxidative phosphorylation as they cannot up-regulate glycolysis. As such, mitochondrial bioenergetic failure can underpin neural death and neurodegenerative disease. In this review, we discuss the links between cellular quality control and neurodegenerative diseases associated with mitochondrial dysfunction, with particular attention to the emerging links between Parkinson's and Gaucher diseases in which defective quality control is a defining factor.
Keywords: Gaucher disease; Parkinson's disease; autophagy; lysosomal storage disorders; lysosome; mitochondria; neurodegeneration; ubiquitin-proteasome system.
© 2013 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.
Figures
Similar articles
-
Unravelling mitochondrial pathways to Parkinson's disease.Br J Pharmacol. 2014 Apr;171(8):1943-57. doi: 10.1111/bph.12433. Br J Pharmacol. 2014. PMID: 24117181 Free PMC article. Review.
-
Mitophagy in neurodegeneration: an opportunity for therapy?Curr Drug Targets. 2011 Jun;12(6):790-9. doi: 10.2174/138945011795528813. Curr Drug Targets. 2011. PMID: 21269269 Review.
-
Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases.Autophagy. 2013 Oct;9(10):1633-5. doi: 10.4161/auto.25878. Epub 2013 Aug 13. Autophagy. 2013. PMID: 23989665 Review.
-
Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.PLoS One. 2019 Jan 11;14(1):e0210617. doi: 10.1371/journal.pone.0210617. eCollection 2019. PLoS One. 2019. PMID: 30633777 Free PMC article.
-
Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases.J Inherit Metab Dis. 2017 Sep;40(5):631-640. doi: 10.1007/s10545-017-0048-0. Epub 2017 May 5. J Inherit Metab Dis. 2017. PMID: 28477283 Review.
Cited by
-
Ultrastructural Abnormalities in Induced Pluripotent Stem Cell-Derived Neural Stem Cells and Neurons of Two Cohen Syndrome Patients.Cells. 2023 Nov 25;12(23):2702. doi: 10.3390/cells12232702. Cells. 2023. PMID: 38067130 Free PMC article.
-
Improving lysosomal ferroptosis with NMN administration protects against heart failure.Life Sci Alliance. 2023 Oct 4;6(12):e202302116. doi: 10.26508/lsa.202302116. Print 2023 Dec. Life Sci Alliance. 2023. PMID: 37793777 Free PMC article.
-
Expert-opinion-based guidance for the care of children with lysosomal storage diseases during the COVID-19 pandemic: An experience-based Turkey perspective.Front Public Health. 2023 Jan 30;11:1092895. doi: 10.3389/fpubh.2023.1092895. eCollection 2023. Front Public Health. 2023. PMID: 36794069 Free PMC article. Review.
-
Genetics of BAG3: A Paradigm for Developing Precision Therapies for Dilated Cardiomyopathies.J Am Heart Assoc. 2022 Dec 6;11(23):e027373. doi: 10.1161/JAHA.122.027373. Epub 2022 Nov 16. J Am Heart Assoc. 2022. PMID: 36382946 Free PMC article. Review.
-
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction.Front Mol Neurosci. 2022 Aug 3;15:934820. doi: 10.3389/fnmol.2022.934820. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35992201 Free PMC article. Review.
References
-
- Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet. 1999;8:567–574. - PubMed
-
- Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006;7:207–219. - PubMed
-
- Agarraberes FA, Dice JF. Protein translocation across membranes. Biochim Biophys Acta. 2001;1513:1–24. - PubMed
-
- Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972–1977. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
